[Form 4] Autonomix Medical, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Autonomix Medical, Inc. (AMIX) director Walter V. Klemp reported a change in beneficial ownership on Form 4 related to a derivative option. The filing shows a transaction dated 08/11/2025 where an option (right to buy) with a revised exercise price of $26.56 and tied to 8,773 underlying common shares was recorded. The option terms in the filing list an exercisable date of 06/21/2025 and expiration of 06/21/2034. The filing explains these figures reflect a 1-for-20 reverse stock split on October 25, 2024, and states the option was cancelled by mutual agreement with the company; the reporting person received no consideration for the cancellation. The Form is signed by an attorney-in-fact on behalf of Mr. Klemp and dated 08/13/2025.

Insights

Corporate Governance Expert

TL;DR: Director Walter Klemp reported a mutual cancellation of an option following a reverse split; the filing records no consideration received.

The Form 4 documents a contractual change affecting an equity derivative held by a company director. Key facts are explicit: the option's exercise price and share counts were adjusted for a 1-for-20 reverse split, and the option was subsequently cancelled by mutual agreement with no cash or other consideration to the reporting person. From a governance perspective, the filing transparently records the administrative outcome and identifies the director as the reporting person; the form is executed via power of attorney. The disclosure is clear and limited to the described transaction.

Securities Analyst

TL;DR: The filing shows a derivative option related to 8,773 underlying shares and an exercise price of $26.56 was cancelled; numbers reflect a reverse split.

The Form lists specific option parameters including exercisable and expiration dates and quantifies the underlying common stock. It also notes adjusted amounts resulting from the 1-for-20 reverse split. The reporting person did not receive consideration for the cancellation, per the explanatory footnote. For analysts, this provides a factual record of a contractual equity change but contains no additional financial terms or transfers to quantify immediate economic impact.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KLEMP WALTER V

(Last) (First) (Middle)

21 WATERWAY AVENUE

SUITE 300

(Street)

THE WOODLANDS TX 77380

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Autonomix Medical, Inc. [ AMIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to buy)	$26.56(1)	08/11/2025		D			8,773(1)	06/21/2025	06/21/2034	Common Stock	8,773	(1)	1,250(2)	D

Explanation of Responses:

1. Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation.

2. Amount represents a revised share amount based on a 1-for-20 reverse stock split from October 25,2024.

	/s/ Trent Smith, Attorney-in-Fact for Walter Klemp	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Autonomix Medical (AMIX)?

The Form 4 was filed on behalf of Walter V. Klemp, who is identified as a Director of Autonomix Medical.

What transaction was reported for AMIX on 08/11/2025?

The filing reports the cancellation of an option (right to buy) dated 08/11/2025, with explanatory notes regarding a reverse stock split adjustment.

What were the option terms disclosed in the Form 4 for AMIX?

The Form lists an exercise price of $26.56, 8,773 underlying common shares, an exercisable date of 06/21/2025, and an expiration date of 06/21/2034.

Did the reporting person receive payment for the option cancellation?

No. The filing explicitly states the option was cancelled by mutual agreement and the reporting person received no consideration for the cancellation.

Why do the share and option amounts appear adjusted in the filing?

The filing explains the amounts and exercise price were revised to reflect a 1-for-20 reverse stock split effective October 25, 2024.